---
title: "Amedisys | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 621.86 M"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/250801683.md"
datetime: "2025-07-30T12:59:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250801683.md)
  - [en](https://longbridge.com/en/news/250801683.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250801683.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/250801683.md) | [繁體中文](https://longbridge.com/zh-HK/news/250801683.md)


# Amedisys | 10-Q: FY2025 Q2 Revenue Beats Estimate at USD 621.86 M

Revenue: As of FY2025 Q2, the actual value is USD 621.86 M, beating the estimate of USD 611.71 M.

EPS: As of FY2025 Q2, the actual value is USD 0.84, missing the estimate of USD 1.29.

EBIT: As of FY2025 Q2, the actual value is USD 48.33 M.

### Home Health Segment

-   **Net Service Revenue**: $396.2 million for Q2 2025, compared to $377.4 million for Q2 2024.
-   **Operating Income**: $67.3 million for Q2 2025, compared to $67.1 million for Q2 2024.
-   **Cost of Service**: $232.0 million for Q2 2025, compared to $216.0 million for Q2 2024.
-   **General and Administrative Expenses**: $94.9 million for Q2 2025, compared to $92.4 million for Q2 2024.

### Hospice Segment

-   **Net Service Revenue**: $215.0 million for Q2 2025, compared to $204.0 million for Q2 2024.
-   **Operating Income**: $54.4 million for Q2 2025, compared to $49.9 million for Q2 2024.
-   **Cost of Service**: $109.1 million for Q2 2025, compared to $104.6 million for Q2 2024.
-   **General and Administrative Expenses**: $50.7 million for Q2 2025, compared to $48.7 million for Q2 2024.

### High Acuity Care Segment

-   **Net Service Revenue**: $10.7 million for Q2 2025, compared to $9.8 million for Q2 2024.
-   **Operating Loss**: -$3.4 million for Q2 2025, compared to -$2.8 million for Q2 2024.
-   **Cost of Service**: $7.4 million for Q2 2025, compared to $6.4 million for Q2 2024.
-   **General and Administrative Expenses**: $5.9 million for Q2 2025, compared to $5.4 million for Q2 2024.

### Cash Flow

-   **Operating Cash Flow**: $63.5 million for the six months ended June 30, 2025, compared to $45.7 million for the same period in 2024.
-   **Free Cash Flow**: Not explicitly stated, but cash used in investing activities was -$2.3 million for the six months ended June 30, 2025.

### Future Outlook and Strategy

-   **Proposed Merger**: Amedisys is involved in a proposed merger with UnitedHealth Group, which is subject to various conditions including regulatory approvals and litigation outcomes.
-   **CMS Payment Updates**: CMS issued updates for hospice and home health payment rates, with expected impacts of a 2.4% increase for hospice and a 6.4% decrease for home health in 2026.

### Unique Metrics

-   **Medicare Revenue**: Represents 68% of consolidated net service revenue for the three and six-month periods ended June 30, 2025.

### Priority

-   **Merger-Related Expenses**: Significant merger-related expenses impacting financial results, totaling $26.3 million for Q2 2025.

### 相关股票

- [Amedisys (AMED.US)](https://longbridge.com/zh-CN/quote/AMED.US.md)

## 相关资讯与研究

- [UnitedHealth Stock Analysis: Generational Buying Opportunity or a Falling Knife to Avoid?](https://longbridge.com/zh-CN/news/281694311.md)
- [UnitedHealth Stock Is Down Nearly 50% over the Past Year, but This 1 Analyst Is Still Betting on UNH to Outperform](https://longbridge.com/zh-CN/news/281566843.md)
- [Why UnitedHealth Stock (UNH) Is Rising Today — And What Raymond James Sees Next](https://longbridge.com/zh-CN/news/281349145.md)
- [Notable analyst calls this week: UnitedHealth, Akamai and Snowflake among top picks](https://longbridge.com/zh-CN/news/281688219.md)
- [Morgan Stanley, Blackstone, Allstate And A Health Care Stock On CNBC's 'Final Trades'](https://longbridge.com/zh-CN/news/281186109.md)